Reviews - Oncology Open access

Circulating IL-6 and survival outcomes in renal cell carcinoma: a systematic review and meta-analysis

Authors

Published
30 September 2025
Section
Reviews - Oncology
DOI
10.4081/aiua.2025.13955

Abstract

Introduction & Objectives: Renal cell carcinoma (RCC) represents the majority of kidney malignancies and is characterized by variable outcomes, even with current systemic therapies. Interleukin-6 (IL-6), a proinflammatory cytokine implicated in tumor progression and immune suppression, has been proposed as a prognostic biomarker in RCC. However, the evidence remains inconsistent due to methodological heterogeneity across studies. Therefore, our study aims to evaluate the prognostic significance of IL-6 in RCC by synthesizing data from published studies, specifically overall survival (OS) and progression-free survival (PFS).
Methods: A systematic meta-analysis was conducted to evaluate the prognostic significance of IL-6 in RCC. Eligible studies were identified through PubMed, ScienceDirect, and ProQuest up to March 2025. Inclusion criteria encompassed original articles measuring pre-treatment serum IL-6 levels in RCC patients and reporting associations with overall survival (OS) or progression-free survival (PFS). Random-effects models were used to compute pooled hazard ratios (HRs) and survival differences.
Results: Nine studies comprising 702 RCC patients were included. Patients with low IL-6 levels had significantly longer OS (difference: 5.36 months; 95% CI: 2.2-8.53; p<0.001; I² = 0%) and PFS (difference: 6.41 months; 95% CI: 1.3-11.53; p=0.01; I² = 48.5%) compared to those with high IL-6. The pooled HR for survival associated with elevated IL-6 was 2.06 (95% CI: -0.23-4.36), with considerable heterogeneity (I² = 89.19%) and borderline statistical significance (p=0.08). Despite variations in study design, sample size, and IL-6 detection methods, elevated IL-6 consistently predicted worse clinical outcomes.
Conclusions: IL-6 is a promising prognostic biomarker in RCC, with elevated levels associated with significantly poorer OS and PFS.

Keywords

References

  1. 1. Hsieh J, Purdue M, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim 2018; 9:1-42.
  2. 2. Petrelli F, Vavassori I, Rossitto M, Dottorini L. Management of metastatic renal cell carcinoma following first-line immune checkpoint therapy failure: a systematic review. Cancers (Basel) 2024;16:2598-610.
  3. 3. Heidegger I, Pircher A, Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 2019;9:1-11.
  4. 4. Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021; 6:263-308.
  5. 5. Pilskog M, Bostad L, Edelmann RJ, et al. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. J Pathol Clin Res 2018; 4:114-23.
  6. 6. Jian SHI, Wang K, Xiong Z, et al. Impact of inflammation and immunotherapy in renal cell carcinoma (Review). Oncol Lett 2020;20:272-84.
  7. 7. Gudbrandsdottir G, Aarstad HH, Bostad L, et al. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). Cancer Immunol Immunother 2021; 70:19-30.
  8. 8. Pilskog M, Nilsen GH, Beisland C, Straume O. Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. Cancer Treat Res Commun 2019; 19:1-5.
  9. 9. Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6 - From the Groupe Français d’Immunothérapie. J Clin Oncol 2004; 22:2371-8.
  10. 10. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012; 13:827-37.
  11. 11. Thiounn N, Pages F, Flam T, et al. Rapid note: IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett 1997;58:121-4.
  12. 12. Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: Correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992;84:1835-6.
  13. 13. Costes V, Liautard J, Picot MC, et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol 1997; 50:835-40.
  14. 14. Akdogan O, Turkmen S, Uyar G, et al. Impact of serum GDF-15 and IL-6 on immunotherapy response in cancer: a prospective study. Cancers (Basel) 2024;16:41-6.
  15. 15. Kays JK, Koniaris LG, Cooper CA, et al. The combination of low skeletal muscle mass and high tumor interleukin-6 associates with decreased survival in clear cell renal cell carcinoma. Cancers (Basel) 2020; 12:1605-15.
  16. 16. Wang Y, Zhang Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. Clin Transl Oncol 2020; 22:835-43.
  17. 17. Gopinathan G, Milagre C, Pearce OMT, et al. Interleukin-6 stimulates defective angiogenesis. Cancer Res 2015; 75:3098-107.
  18. 18. Jian Y, Yang K, Sun X, et al. Current Advance of Immune evasion
  19. mechanisms and emerging immunotherapies in renal cell carcinoma.
  20. Front. Immunol. 2021; 12:1-21.
  21. 19. Ishibashi K, Koguchi T, Matsuoka K, et al. Interleukin-6 induces
  22. drug resistance in renal cell carcinoma. Fukushima J. Med. Sci.
  23. 2018; 64:103-10.
  24. 20. Soler MF, Abaurrea A, Azcoaga P, et al. New perspectives in cancer
  25. immunotherapy: targeting IL-6 cytokine family. J. Immunother.
  26. Cancer 2023; 11:1-13.
  27. 21. Sweeney PL, Suri Y, Basu A, et al. Mechanisms of tyrosine kinase
  28. inhibitor resistance in renal cell carcinoma. Cancer Drug Resist.2023;
  29. 6:858-73.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.